Analysts Set Masimo Co. (NASDAQ:MASI) PT at $179.67

Shares of Masimo Co. (NASDAQ:MASI - Get Free Report) have been given an average rating of "Moderate Buy" by the seven analysts that are presently covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $179.67.

A number of research analysts recently issued reports on the stock. Stifel Nicolaus reissued a "buy" rating and set a $190.00 price target (up from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Piper Sandler boosted their price target on Masimo from $180.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, December 18th. BTIG Research raised their price objective on Masimo from $166.00 to $170.00 and gave the company a "buy" rating in a research report on Monday, October 14th. Wells Fargo & Company boosted their target price on Masimo from $171.00 to $193.00 and gave the stock an "overweight" rating in a report on Wednesday, December 11th. Finally, Raymond James raised their price target on Masimo from $170.00 to $194.00 and gave the company an "outperform" rating in a report on Friday, December 27th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. American Century Companies Inc. raised its position in Masimo by 18.6% in the 2nd quarter. American Century Companies Inc. now owns 10,671 shares of the medical equipment provider's stock worth $1,344,000 after buying an additional 1,671 shares during the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Masimo by 45.9% in the second quarter. Dimensional Fund Advisors LP now owns 525,594 shares of the medical equipment provider's stock worth $66,201,000 after acquiring an additional 165,257 shares during the period. Marshall Wace LLP raised its holdings in shares of Masimo by 5.1% during the second quarter. Marshall Wace LLP now owns 94,798 shares of the medical equipment provider's stock valued at $11,939,000 after purchasing an additional 4,591 shares during the last quarter. Squarepoint Ops LLC bought a new position in Masimo during the second quarter valued at approximately $1,220,000. Finally, Deerfield Management Company L.P. Series C purchased a new stake in Masimo in the second quarter worth approximately $233,000. 85.96% of the stock is owned by institutional investors.

Masimo Trading Up 1.3 %

NASDAQ MASI traded up $2.16 during trading on Friday, hitting $170.24. The company had a trading volume of 337,899 shares, compared to its average volume of 419,156. The company's fifty day moving average is $170.32 and its 200-day moving average is $142.65. Masimo has a one year low of $101.61 and a one year high of $180.97. The company has a current ratio of 2.01, a quick ratio of 1.11 and a debt-to-equity ratio of 0.50. The company has a market cap of $9.11 billion, a price-to-earnings ratio of 117.41 and a beta of 1.01.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $504.60 million during the quarter, compared to the consensus estimate of $502.87 million. During the same period in the prior year, the firm earned $0.63 earnings per share. Masimo's revenue was up 5.4% on a year-over-year basis. On average, sell-side analysts predict that Masimo will post 4.1 earnings per share for the current year.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.